Summary: Researchers have identified a naturally occurring lipid, erucamide, as a key coordinator of the retina’s protective response to injury. The study shows that endogenous erucamide levels fall sharply as light‑sensing photoreceptors degenerate, and that restoring erucamide preserves the retinal neurovascular unit. Rather than acting directly on photoreceptors, erucamide binds to the TMEM19 protein on CD11b⁺ myeloid immune cells, triggering localized signals that protect blood vessels and surrounding neural tissue.
To overcome erucamide’s natural hydrophobicity, the team encapsulated it in engineered porous silicon nanoparticles, enabling stable intraocular delivery and even distribution. In preclinical models, this approach slowed tissue breakdown and stabilized retinal structure and function, pointing to a promising therapeutic avenue for progressive blinding disorders.
Key Facts
- Endogenous signaling decline: Erucamide is a naturally occurring fatty acid amide whose levels fall markedly as photoreceptor cells die during progressive retinal disease.
- Environment‑first therapeutic strategy: Rather than rescuing dying photoreceptors directly, erucamide-based intervention strengthens the supporting neurovascular environment that sustains visual cells.
- TMEM19 receptor mechanism: The protective actions of erucamide require binding to TMEM19 on CD11b⁺ myeloid cells; reducing TMEM19 abolishes the effect.
- Nanoparticle delivery: Porous silicon nanoparticles prevent erucamide from clumping in aqueous environments and provide controlled, uniform release within the eye.
- Potential broad application: By targeting core mechanisms of tissue degeneration and immune–vascular cross talk, this strategy could be relevant to diabetic retinopathy, retinitis pigmentosa, age‑related macular degeneration and other retinal disorders.
Source: Scripps Research Institute
Many diseases that cause vision loss share a common element: progressive breakdown of the retina, the light‑sensing layer at the back of the eye. While some structural changes in this process are known, the molecular signals that shape the retina’s response to injury have been less well characterized.
A research team at Scripps Research, working with colleagues at UC San Diego and the Lowy Medical Research Institute, has now shown that erucamide plays a central role in retinal cell communication during degeneration. Their peer‑reviewed study, published in Nature Neuroscience, reports that erucamide levels decline as photoreceptors begin to die, and that replenishing the lipid reactivates protective cellular responses that support retinal stability.
“The retina does not simply fall apart; it mounts an active response to injury,” says senior author Martin Friedlander of Scripps Research. “Our findings show that erucamide is a signaling molecule involved in coordinating that response.”
The retina relies on continuous communication among neurons, glia, blood vessels and immune cells—collectively the neurovascular unit—to maintain visual function. In diseases such as diabetic retinopathy, retinitis pigmentosa and age‑related macular degeneration, that coordination breaks down: photoreceptors die and vision declines. Prior observations that stem cell‑derived retinal transplants could slow degeneration even after transplanted cells disappeared suggested that transiently released molecules can have lasting protective effects. That clue led the team to search for those molecules.
Using mass spectrometry‑based metabolomics, the researchers screened for small molecules that change during retinal degeneration across multiple validated preclinical models. Among many candidates, erucamide emerged as particularly notable: its concentration fell rapidly in step with the onset of photoreceptor cell death, implying a possible functional role rather than a passive consequence of degeneration.
To test whether restoring erucamide affects disease progression, the investigators developed a delivery system based on porous silicon nanoparticles. Erucamide is highly hydrophobic and tends to aggregate in water‑based solutions used for eye treatments; encapsulation in porous silicon provided stability and allowed controlled, uniform release in the retina.
Rather than acting directly on photoreceptors, erucamide activated CD11b⁺ myeloid immune cells in the retina. The team identified TMEM19 as a binding protein required for this activation: loss or reduction of TMEM19 prevented myeloid cell responses and blocked erucamide’s protective effects. Activated myeloid cells then released angiogenic and neurotrophic signals that helped stabilize both vascular and neural components of the retina.
The result was not a full reversal of degeneration but a meaningful slowing of tissue breakdown through preservation of remaining structure and function. “Targeting the surrounding environment rather than the dying photoreceptors themselves may be a more practical and effective strategy,” explains first author Guoqin Wei, who began this work as a postdoctoral researcher in Friedlander’s lab.
Further work will map the complete signaling cascade downstream of TMEM19, test erucamide signaling across different retinal diseases, and evaluate whether modified erucamide molecules or related lipids provide stronger, longer‑lasting benefits. Improving formulation and delivery methods for clinical use remains a priority, given the challenges posed by erucamide’s hydrophobic nature.
These findings underscore a broader concept: endogenous molecules that decline during disease may be harnessed or reinforced to boost the tissue’s intrinsic protective responses. Enhancing such native signaling could open new therapeutic paths for slowing retinal degeneration when conventional options are limited.
“The aim is to reinforce a signal that already exists,” says Friedlander. “If we can learn to modulate that response safely and precisely, it may offer a new strategy to slow progression in retinal disorders.”
Funding: The study was supported by the Lowy Medical Research Institute; the National Eye Institute (grants R01EY11254 and 5R24EY017540); the California Institute for Regenerative Medicine (grant TR1-01219); the National Science Foundation through the UC San Diego Materials Research Science and Engineering Center (grant DMR-2011924); multiple NIH grants (including 2R01AI132413, R35 GM130385, U01 CA235493 and U01 CA305256); the National Institute on Drug Abuse (grant DA015648); the San Diego Nanotechnology Infrastructure of UC San Diego (NSF grant ECCS-2025752); and the Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship–Doctoral program (NSERC PGS-D).
Key Questions Answered
A: The team used high‑resolution mass spectrometry‑based metabolomics, which profiles hundreds of small lipids and metabolites simultaneously. By tracking multiple preclinical models of retinal degeneration over time, they identified erucamide because its level dropped sharply in parallel with the onset of photoreceptor death, indicating an active role in the disease timeline.
A: Erucamide is highly hydrophobic and poorly soluble in water. Injected in raw form, it aggregates into clumps that are unstable and ineffective in the eye’s aqueous environment. Encapsulation in porous silicon nanoparticles prevents aggregation and enables a controlled, uniform release across damaged retinal layers, improving stability and therapeutic distribution.
A: Directly rescuing dying photoreceptors is difficult once their support systems fail. Erucamide redirects therapy toward CD11b⁺ myeloid cells, which—when activated via TMEM19—release factors that repair and stabilize the neurovascular unit. By restoring the retinal environment first, the remaining photoreceptors receive the structural and trophic support they need to survive longer.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this visual neuroscience research news
Author: Press Office
Source: Scripps Research
Contact: Press Office – Scripps Research
Image: The image is credited to Neuroscience News
Original Research: Open access.
“A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration” by Guoqin Wei et al., Nature Neuroscience.
DOI: 10.1038/s41593-026-02341-w
Abstract
A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration
Breakdown of the neurovascular unit is a central but poorly understood feature of many central nervous system degenerative diseases, including retinal disorders. Primary fatty acid amides have been implicated in regulating interactions between vasculature and neuronal tissue, yet specific molecules and mechanisms have been unclear.
Using an unbiased, high‑resolution metabolomics screen, the investigators found that erucamide—a 22:1 monounsaturated omega‑9 fatty acid amide—is strongly dysregulated during photoreceptor degeneration in mice. In vivo delivery of erucamide via organosilane‑modified porous silicon nanoparticles activated retinal myeloid cells and induced angiogenic and neurotrophic cytokines that limited vascular and neuronal degeneration.
The team identified TMEM19 as a binding protein essential for erucamide‑mediated myeloid activation and subsequent neuroprotection. These findings reveal a previously unrecognized fatty acid amide pathway that modulates neuroimmune interactions in retinal degeneration and nominate erucamide and related analogs as candidate therapeutics.